IMBdx

The company describes its IMBdx platform, including AlphaRiquid profiling and AlphaRiquid100.

IMBdx develops BioPharma solutions for companion diagnostics (CDx).

IMBdx offers the CancerDetect test for minimal residual disease and recurrence monitoring.

IMBdx provides CancerFind for early cancer detection and health checkup services.

IMBDx is expanding into Asian markets, including Japan, to establish a presence using its proprietary liquid biopsy technology. The company joins other Korean firms like NextBioMedical and TomoCube, which have gained attention for their advanced technologies despite limited current sales. Investors anticipate these technologies will enable market dominance in the global liquid biopsy sector.

Sep 2025The Asia Business DailyNews article

IMBDx publishes data on its NGS-based pleural effusion liquid biopsy panel for non-small cell lung cancer (NSCLC) therapy guidance. The company also launches a large-scale multimodal study in Korea for multi-cancer early detection (MCED) using liquid biopsy technology. Both initiatives aim to advance precision oncology through non-invasive blood-based testing.

Mar 2025genomeweb.comNews article

IMBDX applies for an innovative medical technology review for **CancerDetect**, a blood-based test detecting cancer recurrence as early as **three weeks post-surgery**. The precision medicine company specializes in genetic blood analysis for early cancer diagnosis and personalized anticancer treatment guidance. The submission marks a key step toward advancing its ultra-trace cancer detection capabilities.

Aug 2024The Asia Business DailyNews article

IMBDX becomes the sole liquid biopsy company in Korea with verified prescription sales in clinical use. SK Securities highlights its distinction as the only listed firm in the sector generating real-world revenue from medical practitioners. The company’s diagnostic offerings gain recognition among pharmaceutical industry stakeholders.

Jul 2024The Asia Business DailyNews article